Imunofan pretreatment and mammary tumor growth in mice
Animal research · 2013
- What was studied
- 33 male A/Sn mice. Imunofan n=10, IL-2 n=11 and saline n=12.
- Main finding
- Tumor diameter at week 9 among tumor-bearing mice · 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline).
Reported findings and study design
Reported findings
One injection before tumor-cell implantation. Imunofan was reported as 0.2 mL of a 1% solution, IL-2 as 1,000 IU, and saline as 0.2 mL of 0.9% NaCl per mouse. Three days later, mice received 500,000 syngeneic mammary tumor cells subcutaneously. Tumor appearance and diameter were tracked weekly through week 15.
Population or model 33 male A/Sn mice. Imunofan n=10, IL-2 n=11 and saline n=12.
Dose, route and schedule
One injection before tumor-cell implantation. Imunofan was reported as 0.2 mL of a 1% solution, IL-2 as 1,000 IU, and saline as 0.2 mL of 0.9% NaCl per mouse. Three days later, mice received 500,000 syngeneic mammary tumor cells subcutaneously. Tumor appearance and diameter were tracked weekly through week 15.
Protocol source ↗ · Original proceedings report, methods and Tables 1–2.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tumor diameter at week 9 among tumor-bearing mice | 14.1 mm with Imunofan versus 6.9 mm with saline (p=0.029). The IL-2 group measured 13.9 mm (p=0.092 versus saline). | |
| Palpable tumors by week 8 | 70% with Imunofan, 73% with IL-2 and 50% with saline. | |
| Deaths among tumor-bearing mice through week 15 | 100% with Imunofan, 75% with IL-2 and 40% with saline, as reported. The denominators are the animals that developed tumors. | |
| Palpable tumors by week 15 | 70% with Imunofan, 73% with IL-2 and 83% with saline. Earlier detection and faster growth among tumor bearers occurred alongside a lower final proportion with palpable tumors in the treated arms. |
Selected tumor measurements and outcomes
| Outcome | Imunofan | IL-2 | Saline |
|---|---|---|---|
| Assigned | 10 | 11 | 12 |
| Palpable tumor by week 8 | 70% | 73% | 50% |
| Palpable tumor by week 15 | 70% | 73% | 83% |
| Tumor diameter, week 9 | 14.1 mm | 13.9 mm | 6.9 mm |
| Deaths among tumor bearers, week 15 | 100% | 75% | 40% |
The comparison used a small pre-implantation model. The diameter and mortality comparisons were conditional on developing a tumor. The report gives unadjusted tests at several time points and does not provide evidence on human tumor growth or survival. The report prints a 1% solution without clarifying the formulation or injection route for the pretreatment. The actual peptide mass cannot be confirmed.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The comparison used a small pre-implantation model. The diameter and mortality comparisons were conditional on developing a tumor. The report gives unadjusted tests at several time points and does not provide evidence on human tumor growth or survival.
- The report prints a 1% solution without clarifying the formulation or injection route for the pretreatment. The actual peptide mass cannot be confirmed.
Source details
Original conference report
Original proceedings report, methods and Tables 1–2.
Sources checked
Added to the library
Citation
E. V. Moiseeva, S. G. Semushina, D. A. Aronov, A. N. Murashev, A. M. Shishkin, V. K. Bozhenko. Imunofan pretreatment and mammary tumor growth in mice Modern High Technologies, 2013, issue 9, p. 54.